Business context and reporting period
Entity mismatch: The supplied filing is BioZone Pharmaceuticals, Inc.’s Form 10-Q for the quarter and nine months ended September 30, 2012; it is not a Cocrystal Pharma, Inc. filing. The figures below describe BioZone and should not be attributed to Cocrystal.
BioZone reported contract manufacturing and sales of OTC drugs, cosmetics, nutritional supplements, and dermatological products, alongside development of proprietary drug-delivery technology.
Financial performance and position
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Sales | $4.89 million, up 24.5% year over year | $13.32 million, up 49.0% |
| Gross profit / margin | $2.02 million / approximately 41%, versus $2.09 million / 53% | $5.50 million / approximately 41%, versus $3.73 million / 42% |
| Operating income (loss) | $362,318, versus loss of $2.22 million | $33,623, versus loss of $3.11 million |
| Net loss | $98,730, versus $2.50 million | $4.46 million, versus $3.61 million |
| Interest expense | $482,960, versus $283,411 | $4.97 million, versus $505,606 |
At September 30, 2012, cash was $82,621; current assets were $3.64 million and current liabilities $5.42 million, resulting in negative working capital of $1.78 million. Shareholders’ deficiency was $74,927. Balance-sheet debt included $1.23 million of convertible notes, $1.10 million due to a shareholder, and $3.11 million of long-term debt, including its current portion. The shareholder note was due on demand and its balance was disputed.
For the first nine months, operating cash use was $1.64 million, investing cash use was $320,116, and financing provided $1.62 million. Cash declined by $333,712 from year-end 2011. Reported nine-month interest expense included substantial noncash debt-discount and financing effects.
Material changes versus the prior comparable period
- Nine-month sales increased 49%, while gross margin slipped to approximately 41% from 42%; management attributed the quarterly margin decline mainly to higher raw-material costs.
- Nine-month operating expenses fell 20%, principally because the prior-year period included $1.95 million of stock-based compensation. R&D spending increased with the opening of a Princeton research facility and addition of five staff members.
- Nine-month net loss grew by $847,892, chiefly reflecting sharply higher interest expense associated with 2012 convertible-note and warrant financing, despite a gain from revaluing derivative instruments.
- Common shares issued and outstanding were 63,142,969 at September 30, compared with 55,181,165 at December 31, 2011; substantial warrant exercises and other equity transactions occurred during the period.
Outlook, risks, contingencies, and unusual items
- Going concern: Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing negative working capital, shareholder deficiency, and losses in prior fiscal years. Continued operations depend on financing and successful future operations. Management said it was reviewing manufacturing costs and sales programs; no quantified forecast or formal financial guidance was provided.
- Customer concentration and seasonality: Two customers represented approximately 26% and 25% of nine-month sales. Management said roughly two-thirds of annual revenue is generated in the second half, partly reflecting seasonal cough-and-cold product demand.
- Litigation: A former executive sought $23 million in damages in litigation against the company and others. BioZone disputed the allegations. BioZone separately sought at least $2 million, cancellation of 6.65 million shares, and other relief in its suit against the former executive and a property entity. A separate contract-related suit also remained pending; the filing did not provide a clear estimated loss for these matters.
- Other exposures: BioZone consolidated a variable-interest entity that owned its manufacturing facility and guaranteed its mortgage; the stated maximum exposure was $2.61 million. The company also reported a dispute over the amount due to a former executive shareholder, while recording the full amount claimed.
- Controls: Management concluded disclosure controls were ineffective because of material weaknesses in internal control over financial reporting; no material control changes were reported during the quarter.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is for BioZone Pharmaceuticals, Inc., not Cocrystal Pharma, Inc.
- Assess near-term liquidity, financing access, debt maturities, security interests, and the company’s stated going-concern uncertainty.
- Review the drivers and recurrence of the unusually high interest expense and derivative-related accounting, including potential dilution from equity-linked securities.
- Monitor customer concentration, gross-margin trends, and seasonal sales patterns.
- Check subsequent developments and potential financial exposure from the disclosed lawsuits and shareholder-note dispute.
- Review remediation of the disclosed material weaknesses in internal controls.